Moxa, I believe what you're suggesting may be very

New Post Public Reply Private Reply Replies (1) Message Board
GaryM moxaman #13328
446
Moxa,

I believe what you're suggesting may be very possible, but it's not documented in what we've been able to look at. The trial filing that's in the clinical trials database is purely a Phase 1 in healthy patients. Is it possible that since then the trial as it's being run has become a Phase 1/2 Trial where once safety is proven as Phase 1, with the most effective dosage determined, they move into a Phase 2 portion where the drug can be tried with patients who have psoriasis. This is not what the timeline shows, it shows a separate Phase 2, but it's not impossible that one has morphed into the other. Even if that should be the case, I see no reason the company cannot say the Phase 1 portion of the trial has successfully ended, and give the top line info from that part of the trial. It would be quite positive if they also said we are now trying the drug in patients with the disease, and give us some guidance as to how many patients and how long they anticipate that taking.

Companies use the clinical trials database to attract patients to trials. It may very well be true that OWCP doesn't need this. It is very possible that Sheeba, and other clinical sites in Israel already have plenty of volunteers lined up, and their is no law that says that to do a trial you must be in the clinical trials database, in fact it seems that in Israel the full authority that must be convinced is the IRB and I have no idea how open they are to making modifications during the trial. Going from a Phase 1 to a Phase 1/2 would be such a modification.

I should add, we have no guidance on what the protocol of the fibromyalgia trial is, and it should be underway if the last update we've seen from the company is true as best I remember.

In many ways, OWCP is like that iceberg often seen in photos where so little can be seen, but so much exists below the water where it's invisible to practically everyone.

Gary

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Formula GT: Revolutionizing Motorsport with Hypercar Innovations

Updated Category News Views 552

Formula GT Global Launch Set to Transform Motorsport A remarkable dawn is heralded in the motorsport world as Formula GT officially announces its global launch, scheduled for Spring 2026. This groundbreaking league integrates advanced technology, high-speed capabilities, and the most prestigious hypercars, promising to redefine racing as we know it. Exciting Launch Gala...

Continue Reading
Settlement Between Ultra Lithium and Power Minerals Finalized

Updated Category News Views 136

Understanding the Settlement Agreement Ultra Lithium Inc. has made headlines with its recent settlement agreement with Power Minerals Limited regarding their convertible loan agreement. This agreement comes after months of negotiations and aims to outline specific terms beneficial to both companies. Key Terms of the Agreement The settlement agreement involves several...

Continue Reading
Revolutionizing Cooking with Typhur's Sync Gold Meat Thermometers

Updated Category News Views 160

Introducing the Revolutionary Sync Gold Series Typhur, a frontrunner in smart kitchen technology, is excited to announce its latest innovation: the Sync Gold Series wireless meat thermometers. These thermometers are built with cutting-edge Sub-1G technology, which takes your cooking precision to the next level. The Sync Gold Series features two versatile models: the Sync...

Continue Reading
Analyzing the Short Interest Trends for AutoZone Inc

Updated Category News Views 80

Understanding AutoZone Inc's Short Interest AutoZone Inc (NYSE: AZO) has recently seen a noteworthy rise in its short interest, which now stands at approximately 5.91% higher than its previous report. This increase translates to around 317 thousand shares being sold short, representing 2.15% of the total regular shares available for trading. Given its trading patterns, it...

Continue Reading
Parex Resources Plans Share Buyback to Enhance Shareholder Value

Updated Category News Views 319

Parex Resources Moves Forward with New Share Buyback Initiative Parex Resources Inc. (TSX: PXT) is excited to share its latest development, which involves a normal course issuer bid that has received approval from the Toronto Stock Exchange. The company aims to purchase up to 8,621,348 common shares, with a goal of enhancing shareholder value while demonstrating...

Continue Reading